LOH11CR2A Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP8651a
Background:
LOH11CR2A may play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.
Other Names:
von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, VWA5A, BCSC1, LOH11CR2A
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP8651a was selected from the N-term region of human LOH11CR2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: VWA5A
Gene ID: 4013
Primary Accession: O00534
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
LOH11CR2A may play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.
Other Names:
von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, VWA5A, BCSC1, LOH11CR2A
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP8651a was selected from the N-term region of human LOH11CR2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: VWA5A
Gene ID: 4013
Primary Accession: O00534
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review